SCHEMBL2166641

SCHEMBL2166641

Cc1cccc(CN2CCN(c3cccc4nc(N)nc(N)c34)CC2)c1F

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DCPS Q96C86 9/20 0.46
CYP2D6 P10635 1/20 0.46
HTR7 P34969 2/20 0.41
RAB9A P51151 2/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
KMT2A Q03164 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
USP2 O75604 2/20 0.40
HSD17B10 Q99714 1/20 0.40
ALDH1A1 P00352 2/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
DHFR P00374 3/20 0.39
KDM4E B2RXH2 1/20 0.39
PLA2G1B P04054 1/20 0.39
ATG4B Q9Y4P1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2165238 0.90 KMT2A (0.51) DCPSCYP2D6HTR7RAB9AMEN1
SCHEMBL2166247 0.86 DCPS (0.61) DCPSCYP2D6RAB9AKMT2AUSP2
SCHEMBL2167390 0.81 ALDH1A1 (0.64) DCPSCYP2D6RAB9AALDH1A1MAPT
SCHEMBL2165395 0.81 DRD2 (0.56) DCPSCYP2D6RAB9AALDH1A1DHFR
SCHEMBL2165879 0.81 DCPS (0.51) DCPSCYP2D6KMT2AALDH1A1DHFR
SCHEMBL12404416 0.79 DCPS (0.48) DCPSCYP2D6RAB9ANPC1MAPT
SCHEMBL2166082 0.78 DCPS (0.58) DCPSRAB9AMEN1NPC1KMT2A
SCHEMBL2165096 0.78 DCPS (0.68) DCPSCYP2D6KMT2AALDH1A1DHFR
SCHEMBL2164517 0.77 DCPS (0.78) DCPSCYP2D6DHFR
SCHEMBL2166006 0.77 KDM4E (0.53) DCPSRAB9AALDH1A1MAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069316-B1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2015-10-07 EP disclosed
EP-2615086-A1 2,4-Diaminoquinazolines for the treatment of spinal muscular atrophy Families of Spinal Muscular Atrophy (US) 2013-07-17 EP disclosed
US-7985755-B2 2,4-diaminoquinazolines for spinal muscular atrophy FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2011-07-26 US disclosed
EP-2069316-A1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY Families of Spinal Muscular Atrophy (US) 2009-06-17 EP disclosed
US-20090042900-A1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY DECODE CHEMISTRY, INC. (US) 2009-02-12 US disclosed
WO-2008016973-A1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY FAMILIES OF SPINAL MUSCULAR ATROPHY (US) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042900-A1 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY SMN1; SMN2, MUSK, MYT1 DCPS 1366/4885CYP2D6 3869/4885HTR7 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.